ASCO 2019 | Atezolizumab for TNBC

Erika Hamilton

Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville. TN, discusses the use of
atezolizumab for the treatment of triple-negative breast cancer (TNBC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
Related videos
2:01
PATRIOT: ATR inhibitor monotherapy in advanced solid tumors
Kevin Harrington
3:01
Update on oncolytic viruses for cancer treatment
Kevin Harrington
3:58
Updates on HPV+ oropharyngeal cancer - de-escalation and reducing costs with cisplatin
Hisham Mehanna
2:26
Cytotoxic contamination in wards
Matthew Fowler
1:55
Totally Implantable Vascular Access Device (TIVAD) service for patients with metastatic cancer
Matthew Fowler
Breast Cancer, General
Atezolizumab
ASCO 2019
Interview
2nd June 2019
More from Erika Hamilton
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
Social media: research opportunities
Updates in HR-Positive mBCa
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals